Advancements in research to mitigate residual risk of atherosclerotic cardiovascular disease
Abstract Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide. Although low-density lipoprotein cholesterol (LDL-C) levels are well controlled by current therapies, the residual risk of ASCVD remains, and adverse cardiovascular events remain a major clinical problem...
Saved in:
| Main Authors: | Fan Shi, Jinjin Dou, Xiwu Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-025-03006-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The interaction between blood lipids and ASCVD increases the risk of DKD: a nonlinear relationship transforms into a linear relationship, a cross-sectional study
by: Huan Li, et al.
Published: (2025-08-01) -
An equation for estimating low-density lipoprotein-triglyceride content and its use for cardiovascular disease risk stratification
by: Anna Wolska, et al.
Published: (2024-10-01) -
Association of sdLDL-C/LDL-C ratio with atherosclerotic cardiovascular disease: a case-control study
by: Yuxin Yang, et al.
Published: (2025-06-01) -
Reduced plasma levels of neuregulin-1 are associated with adverse outcomes in patients with atherosclerotic cardiovascular disease
by: Jie Liu, et al.
Published: (2025-07-01) -
Elevated Fasting C-Peptide Levels Correlate with Increased 10-Year Risk of Atherosclerotic Cardiovascular Disease in Newly Diagnosed Type 2 Diabetes Patients
by: Zha XY, et al.
Published: (2025-01-01)